Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is projected to release its earnings data before the market opens on Monday, March 24th. Analysts expect Enveric Biosciences to post earnings of ($6.00) per share for the quarter.
Enveric Biosciences Trading Up 0.6 %
NASDAQ:ENVB opened at $1.74 on Friday. Enveric Biosciences has a 12-month low of $1.13 and a 12-month high of $17.85. The firm has a market cap of $1.18 million, a PE ratio of -0.05 and a beta of 0.47. The stock has a fifty day moving average price of $2.65 and a 200 day moving average price of $5.04.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Enveric Biosciences in a research note on Thursday, March 6th.
About Enveric Biosciences
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
See Also
- Five stocks we like better than Enveric Biosciences
- Stock Average Calculator
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
- Health Care Stocks Explained: Why You Might Want to Invest
- Alphabet Stock Becomes a Low-Risk, High-Reward Play
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Affirm Stock: Should You Buy the Dip After Walmart Setback?
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
